Tag:
ebola
Latest Headlines
Latest Headlines
J&J;, Merck to advance Ebola vaccines in Africa, but their fate rests in WHO's hands
Johnson & Johnson is ready to start trialing its Ebola vaccine in Africa, where Merck and NewLink are preparing to take theirs into Phase III. GlaxoSmithKline is also testing its jab there. But while thousands of healthcare workers have volunteered to participate in Ebola vaccine trials, the decision to mass-vaccinate against the disease is still up in the air.
NewLink nets $20M Ebola milestone from Merck
NewLink's Ebola vaccine tie-up with Merck continues to pay off.
Novavax's Ebola vaccine is in hot pursuit of GSK, Merck, J&J; candidates
Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.
Scientists in search of next-generation Ebola vaccines as outbreak dwindles
The current Ebola outbreak may be starting to wane, but scientists agree they'll need a stockpile of vaccines to tackle the next one. And that means developing next-generation shots that can fight off multiple strains.
First batch of GSK/NIH Ebola candidate shipped for Phase III trial in Liberia
GlaxoSmithKline's Ebola candidate will be the first of several experimental vaccines to undergo large-scale clinical trials. On Friday, the company shipped an initial batch of 300 vials of the vaccine, ChAd3, to Liberia, one of the main countries affected by Ebola.
J&J; forms consortia to accelerate Ebola vaccine development, gets €100M boost from IMI
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.
Late-stage trials for Glaxo, Merck Ebola jabs could begin this month in West Africa
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
Zydus Cadila ups vaccines game with programs for Ebola, Congo fever
The latest drugmaker diving into the Ebola vaccine race? India's Zydus Cadila.
Johnson & Johnson is third to bring Ebola vaccine to trials, but is it too late?
Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J;'s candidate come too late to catch up with its rivals and help combat the current epidemic?
Swiss trial of Merck/NewLink Ebola vaccine resumes at lower dose
The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.
